AU
UK
CA
NZ
IND
US
ALeadershipAppointment Drives a Sharp Market Response
A Drug That Worked Once, and Then Did Not
ARevenueBeat That Moved the Market
A Clinical Milestone in One of Oncology's Toughest Indications
A Compounding Crisis
Key Highlights
A 42 Per Cent Rout Before the Opening Bell
Boston Scientific Corporation (NYSE:BSX), one of the largest US-listed medical-device manufacturers, has delivered a first-quarter 2026 result that has sparked one of the more nuanced reactions in healthcare equities this year. The company beat consensus expectations on adjustedEarnings, reported strong organic growth in several …
Please wait processing your request...